弗吉尼亚州男子被控把贴错标签的处方药原料卖往全美：涉案发货约1,732次
美国弗吉尼亚州 Bluefield 市男子 Mikhail Mosley 与他经营的公司 Chemsavers 被联邦大陪审团以九项罪名起诉，指控他们把贴错标签的处方药投入市场销售。起诉书指控两人犯有共谋诈骗美国、邮件诈骗、把贴错标签的药品投入州际商业，以及经营未注册的生产设施等罪名。美国司法部弗吉尼亚西区联邦检察官办公室本周公布了这份起诉书。
据起诉书，Chemsavers 公开销售多种受《联邦食品、药品和化妆品法》管制的药物活性成分与处方药成分，其中包括用于帮助清除体内放射性铯和铊的处方药普鲁士蓝、用于治疗高铁血红蛋白血症的亚甲蓝、勃起功能障碍处方药的活性成分西地那非，以及获食品药品监管局 FDA 批准用于乳腺癌相关治疗的他莫昔芬。
起诉书称，在2021年1月至2026年5月间，Mosley 与 Chemsavers 约1,732次把贴错标签的普鲁士蓝送入州际商业流通，同期约108次送入贴错标签的亚甲蓝。两人还被指控在2025年7月22日与9月18日，分别以每包1,681.11美元的价格，向一名冒充顾客的 FDA 犯罪调查办公室卧底探员出售100克装的西地那非原料；2025年11月21日，又向卧底探员出售5克他莫昔芬原料。
代理联邦检察官 Robert N. Tracci 表示，给处方药贴错标签是威胁公民安全、损害公众对合法处方药信任的犯罪，该办公室将继续与 FDA 等伙伴合作追责。FDA 犯罪调查办公室华盛顿都会区外勤办公室特别探员主管 Marie Maguire 表示，进入州际商业流通的药品一般必须获批准、并在可接受 FDA 检查监督的注册设施内生产，被告被指绕开了这些重要保障。
此案由 FDA 犯罪调查办公室调查，助理联邦检察官 Danielle Stone 与 Randy Ramseyer 负责起诉。起诉书只是指控，Mosley 与 Chemsavers 在被证明有罪之前均被推定无罪。（来源：美国司法部弗吉尼亚西区联邦检察官办公室）
Virginia Man Charged With Selling Misbranded Prescription Drug Ingredients Nationwide: Some 1,732 Shipments Alleged
Mikhail Mosley, 38, of Bluefield, Virginia, and Chemsavers, the company he owns and operates, have been charged in a nine-count federal indictment with mislabeling prescription drugs, the U.S. Attorney's Office for the Western District of Virginia announced this week. The indictment charges Mosley and Chemsavers with conspiracy to defraud the United States, mail fraud, introduction of misbranded drugs into interstate commerce, and operating an unregistered manufacturing facility.
According to the indictment, Chemsavers advertised for sale numerous substances that are active pharmaceutical ingredients or prescription drug components regulated under the Federal Food, Drug, and Cosmetic Act. They included Prussian Blue, a prescription drug used to help remove radioactive cesium and thallium from the body; Methylene Blue, used to treat the dangerous blood disorder methemoglobinemia; Sildenafil Citrate, the active ingredient in prescription drugs for erectile dysfunction; and Tamoxifen Citrate, approved by the Food and Drug Administration (FDA) for several indications related to breast cancer.
The indictment alleges that between January 2021 and May 2026, Mosley and Chemsavers introduced misbranded Prussian Blue into interstate commerce on approximately 1,732 occasions, and misbranded Methylene Blue on approximately 108 occasions during the same period. They are also charged with selling 100-gram packages of Sildenafil Citrate on July 22, 2025, and September 18, 2025, for $1,681.11 each to an undercover FDA Office of Criminal Investigations agent posing as a customer, and with selling 5 grams of Tamoxifen Citrate to an undercover agent on November 21, 2025.
"Mislabeling prescription drugs is a crime that threatens the safety of our citizens and undermines public confidence in lawful prescription drugs," said First Assistant United States Attorney Robert N. Tracci. Marie Maguire, Special Agent in Charge of the FDA Office of Criminal Investigations' Metro Washington Field Office, said drugs distributed in interstate commerce generally must be approved and manufactured in a registered facility subject to FDA inspection and oversight, safeguards the defendants are charged with undermining.
The case is being investigated by the FDA Office of Criminal Investigations. Assistant United States Attorneys Danielle Stone and Randy Ramseyer are prosecuting the case. An indictment is merely an allegation, and Mosley and Chemsavers are presumed innocent until proven guilty beyond a reasonable doubt. (Source: U.S. Attorney's Office for the Western District of Virginia)
来源：美国司法部弗吉尼亚西区联邦检察官办公室
发布：GSM·美国（发布链接）
图片来源：图：美国食品药品监管局 FDA 总部大楼。美国食品药品监管局发布，公共领域，经 Wikimedia Commons。 / Photo: U.S. Food and Drug Administration headquarters. By the U.S. Food and Drug Administration, public domain, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
